Please use this identifier to cite or link to this item:
Authors: Shur, Natalie
Major, Rupert
Papamargaritis, Dimitris
Webb, David
Khunti, Kamlesh
Shepherd, David
Brunskill, Nigel
First Published: 24-May-2016
Presented at: 53rd ERA-EDTA Congress, Vienna, AUSTRIA
Start Date: 21-May-2016
End Date: 24-May-2016
Publisher: Oxford University Press (OUP) for European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Citation: Nephrology Dialysis Transplantation, 2016, 31(suppl_1), pg. i69
Abstract: Introduction and Aims: Chronic kidney disease (CKD) and diabetes mellitus (DM) are important risk factors for cardiovascular (CV) disease and are associated with increased CV events. Multimorbidity with both DM and CKD is increasing in prevalence. Appropriate monitoring and use of renin-angiotensin system antagonists, as well as optimising blood pressure and lipid levels, are important strategies in the management of people with CKD. Whether the presence or absence of DM influences the clinical assessment of CKD is unknown. We aimed to establish rates of other comorbidities and commonly used medication prescription rates. We also aimed to establish if DM affected the likelihood of confirmatory eGFR or urinary protein assessment being performed. Methods: We analysed the baseline cohort of the PSP-CKD study, a large United Kingdom primary care CKD clinical trial, to study a subgroup with DM. DM was defined using HbA1c, the use of DM medications or a Read code diagnosis of DM. Co-morbidities were based on Read codes and medications on prescription records. Comparison was made to members of the cohort with CKD but not known to have diabetes. Results: The DM subgroup consisted of 5,842 individuals, 55.6% of whom were female. Mean age was 74.1 years (standard deviation (SD) 10.5 years). Mean MDRD eGFR was 49.2 ml/min/1.73m2, 73.5% were CKD stage 3A. Individuals with DM, compared with those without DM, had a lower mean MDRD eGFR (49.4 ml/min/1.73m2 versus 54.4 ml/min/1.73m2, t-test p<0.001) and were more likely to have had a second confirmatory eGFR (76.1% versus 62.7%, Pearson Chi-squared p<0.001) and their urinary protein assessed (86.0% versus 66.5%, Pearson Chi-squared p<0.001). Of those with a urine assessment, 69.9% had stage A1 proteinuria. Mean HbA1c was 7.3% (SD 1.4%). Mean systolic blood pressure was 134.2 mmHg (SD 16.5 mmHg) and diastolic 73.1 mmHg (SD 10.2 mmHg). 76.4% were hypertensive and 38.9% had had a previous cardiovascular event. 74.3% were prescribed either an ACE inhibitor or ARB. 2.6% were prescribed both an ACE inhibitor and ARB, 74.2% were receiving a statin and 48.8% aspirin. Conclusions: Patients with CKD and DM have a significantly lower eGFR compared with patients with CKD alone. In addition, patients with CKD and DM were monitored more closely with confirmatory eGFR or urinary protein assessment compared to patients with CKD alone. RAS blockade medication and statins were prescribed to three quarters and aspirin to just under a half. Overall, the assessment and management of multimorbid patients with both CKD and DM is more thorough than those with CKD alone.
DOI Link: 10.1093/ndt/gfw146.05
ISSN: 0931-0509
eISSN: 1460-2385
Version: Post-print
Status: Peer-reviewed
Type: Conference Paper
Rights: Copyright © 2016, Oxford University Press (OUP) for European Renal Association - European Dialysis and Transplant Association (ERA-EDTA). Deposited with reference to the publisher’s open access archiving policy. (
Description: Abstract only
Appears in Collections:Conference Papers & Presentations, Dept. of Health Sciences

Files in This Item:
File Description SizeFormat 
ERA-DM cohort FINAL.pdfPost-review (final submitted author manuscript)9.63 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.